Cutera, Inc. (NASDAQ:CUTR – Get Rating) was the recipient of a giant progress briefly curiosity in the course of the month of December. As of December fifteenth, there was quick curiosity totalling 4,090,000 shares, a progress of 13.0% from the November thirtieth complete of three,620,000 shares. Primarily based on a mean each day buying and selling quantity, of 326,500 shares, the short-interest ratio is presently 12.5 days.
Wall Avenue Analyst Weigh In
A lot of analysis analysts have just lately commented on CUTR shares. StockNews.com started protection on Cutera in a analysis report on Wednesday, October twelfth. They set a “promote” score on the inventory. Stephens decreased their goal value on Cutera from $78.00 to $68.00 and set an “chubby” score on the inventory in a analysis word on Wednesday, December twenty eighth. One analyst has rated the inventory with a promote score and three have issued a purchase score to the inventory. Based on MarketBeat.com, the corporate has a consensus score of “Average Purchase” and a mean value goal of $68.25.
Cutera Worth Efficiency
Shares of Cutera stock traded up $0.83 throughout buying and selling on Monday, hitting $44.22. 8,714 shares of the inventory traded palms, in comparison with its common quantity of 347,789. The corporate has a fast ratio of three.16, a present ratio of three.73 and a debt-to-equity ratio of 19.38. The inventory has a market cap of $867.38 million, a price-to-earnings ratio of -10.50 and a beta of 1.68. The agency’s fifty day transferring common is $45.25 and its 200-day transferring common is $45.03. Cutera has a 52 week low of $31.62 and a 52 week excessive of $74.38.
Cutera (NASDAQ:CUTR – Get Rating) final issued its earnings outcomes on Thursday, November third. The medical gadget firm reported ($0.62) earnings per share for the quarter, lacking the consensus estimate of ($0.24) by ($0.38). The corporate had income of $62.81 million for the quarter, in comparison with analysts’ expectations of $62.65 million. Cutera had a damaging web margin of 31.31% and a damaging return on fairness of 225.70%. Analysis analysts count on that Cutera will submit -2.39 EPS for the present fiscal 12 months.
Institutional Traders Weigh In On Cutera
Institutional buyers have just lately purchased and offered shares of the inventory. Captrust Monetary Advisors lifted its holdings in Cutera by 592.2% within the 1st quarter. Captrust Monetary Advisors now owns 533 shares of the medical gadget firm’s inventory value $37,000 after shopping for a further 456 shares in the course of the interval. Almanack Funding Companions LLC. bought a brand new stake in Cutera within the third quarter value roughly $25,000. Monetary Gravity Asset Administration Inc. bought a brand new stake in Cutera within the 2nd quarter value roughly $1,976,000. Rockefeller Capital Administration L.P. lifted its holdings in Cutera by 2,861.8% within the third quarter. Rockefeller Capital Administration L.P. now owns 1,007 shares of the medical gadget firm’s inventory value $45,000 after shopping for a further 973 shares in the course of the interval. Lastly, HighMark Wealth Administration LLC lifted its holdings in Cutera by 1,515.2% within the 2nd quarter. HighMark Wealth Administration LLC now owns 1,066 shares of the medical gadget firm’s inventory value $40,000 after shopping for a further 1,000 shares in the course of the interval.
Cutera Firm Profile
Cutera, Inc, a medical gadget firm, researches, develops, manufactures, markets, and companies laser and energy-based aesthetics methods for practitioners worldwide. The corporate presents Secret PRO, a tool that makes use of fractional CO2 for pores and skin resurfacing and radio frequency (RF) microneedling for deep dermal reworking; truSculpt flex, a bio-electrical muscle stimulation gadget to deal with sufferers in any respect health ranges; excel V+, a vascular and benign pigmented lesion remedy platform; truSculpt iD, for the non-surgical physique sculpting market; and Secret RF, a fractional RF microneedling system for tissue coagulation and hemostasis.
This prompt information alert was generated by narrative science expertise and monetary information from MarketBeat to be able to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial crew previous to publication. Please ship any questions or feedback about this story to firstname.lastname@example.org.
Earlier than you think about Cutera, you may need to hear this.
MarketBeat retains observe of Wall Avenue’s top-rated and finest performing analysis analysts and the shares they advocate to their shoppers every day. MarketBeat has recognized the five stocks that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Cutera wasn’t on the checklist.
Whereas Cutera at the moment has a “Purchase” score amongst analysts, top-rated analysts consider these 5 shares are higher buys.